Review
Drug Class Review on HMG-CoA Reductase Inhibitors (Statins): Final Report [Internet]
Portland (OR): Oregon Health & Science University; 2006 Aug.
Affiliations
- PMID: 20496454
- Bookshelf ID: NBK10704
Item in Clipboard
Review
Drug Class Review on HMG-CoA Reductase Inhibitors (Statins): Final Report [Internet]
Excerpt
In the United States, coronary heart disease (CHD) and cardiovascular disease (CVD) account for nearly 40% of all deaths each year. High levels of cholesterol, or hypercholesterolemia, are an important risk factor for CHD. The 3-hydroxy-3-methylglutaryl-coenzyme (HMG-CoA) reductase inhibitors, also known as statins, are the most effective class of drugs for lowering serum low-density lipoprotein cholesterol (LDL-c) concentrations. The purpose of this review is to compare the efficacy and adverse effects of different statins.
Copyright & 2006, Oregon Health & Science University, Portland, Oregon.
Similar articles
-
Drug Class Review: HMG-CoA Reductase Inhibitors (Statins) and Fixed-dose Combination Products Containing a Statin: Final Report Update 5 [Internet].Portland (OR): Oregon Health & Science University; 2009 Nov. Portland (OR): Oregon Health & Science University; 2009 Nov. PMID: 21089253 Free Books & Documents. Review.
-
A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia.Clin Ther. 1999 Mar;21(3):536-62. doi: 10.1016/S0149-2918(00)88308-3. Clin Ther. 1999. PMID: 10321422
-
Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor therapy in the managed care era.Am J Cardiol. 1996 Sep 26;78(6A):32-41. doi: 10.1016/s0002-9149(96)00660-1. Am J Cardiol. 1996. PMID: 8875973
-
Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.Clin Pharmacokinet. 1997 May;32(5):403-25. doi: 10.2165/00003088-199732050-00005. Clin Pharmacokinet. 1997. PMID: 9160173 Review.
-
The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. Estimating the benefits of increasing HDL-C.JAMA. 1995 Apr 5;273(13):1032-8. JAMA. 1995. PMID: 7897787
Publication types
Grants and funding
The funding source, the Center for Evidence-based Policy, is supported by 17 organizations, including 15 state Medicaid programs. These organizations selected the topic and had input into the Key Questions for this review. The content and conclusions of the review are entirely determined by the Evidence-based Practice Center researchers. The authors of this report have no financial interest in any company that makes or distributes the products reviewed in this report.
LinkOut - more resources
Full Text Sources
